PFS increase but no OS increase for niraparib in advanced ovarian cancer
24:35
ESMO 2024: Highlights and analysis
4:19
Watchful waiting vs intravesical BCG in high grade pT1 bladder cancer
4:27
Nivolumab and ipilimumab shows a significantly higher OS rate in nccRCC compared to standard of ...
6:31
PRIMA: Frontline Niraparib Maintenance Therapy in Ovarian Cancer
57:11
Personalizing Advanced Ovarian Cancer Treatment With PARP Inhibitors and Novel Approaches
17:18
Boost Your Bone Density with These 6 Life-Changing Tips
8:02
tagesthemen-Interview: Merz verteidigt Asyl-Abstimmung im Bundestag
10:19